ArticleAlzheimer's research & therapy2026
Association of functional brain alterations with β-amyloid, tau, and cognitive decline in Alzheimer's disease.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRegional functional activity plays a critical role in the cognitive performance of both aging individuals and Alzheimer’s disease (AD). To better understand the pathologies and clinical progression patterns of AD, the investigation of the associations of regional functional brain alterations with β-amyloid (Aβ) plaques, tau tangles, and cognitive decline in AD is essential.
methodsWe recruited 179 participants (mean age of 69.7 years, 61% female) who underwent concurrent [18F]-Florbetapir Aβ PET imaging, [18F]-PI-2620 tau PET imaging, resting functional MRI, and cognitive assessments, after which we classified these participants into A-/T- (N = 35), A-/T+ (N = 11), A+/T- (N = 53), and A+/T+ (N = 80) groups according to the thresholds of the Aβ and tau PET standardized uptake value ratio (SUVR). We subsequently compared the group differences in mean regional homogeneity (ReHo) values and explored the correlations between ReHo index scores and Aβ burden, tau deposition, and cognitive scores using general linear models, including age, sex, education, hippocampus volume, and total intracranial volume as covariates.
resultsWe detected neuronal hyperactivity and hypoactivity in the angular gyrus, cuneus, lingual gyrus, and parahippocampal gyrus, which are mainly distributed across the default mode and salience networks; moreover, they are associated with regional Aβ burden and tau deposition encompassing the AD spectrum. Furthermore, we confirmed that elevated cortical Aβ accumulation and tau deposition mainly induce decreases in regional functional activity in AD. Finally, we observed that Aβ- and tau-related regional functional brain alterations showed significant indirect associations with the relationships between Aβ burden (β = -0.08, [95% ci, -4.22~ -0.75], p = 0.01), tau deposition (β = -0.17, [95% ci, -11.04~-4.07], p < 0.0001), and cognitive performance. These findings indicate that abnormal functional activity is associated with both AD hallmark pathologies and cognitive decline, in a manner consistent with a potential mediating role.
conclusionsThis study revealed that cortical Aβ and tau aggregation may alter functional activity (as reflected by ReHo), thus further leading to cognitive decline in patients with AD. These findings provide novel insights into how Aβ and tau-associated functional activity affect cognitive decline in AD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.